- 本カテゴリの商品を2500円以上購入で買取金額500円UPキャンペーン対象商品です。商品出荷時に買取サービスでご利用いただけるクーポンをメールにてご案内させていただきます。 詳細はこちら (細則もこちらからご覧いただけます)
Epigenetic Cancer Therapy (英語) ハードカバー – 2015/7/30
Kindle 端末は必要ありません。無料 Kindle アプリのいずれかをダウンロードすると、スマートフォン、タブレットPCで Kindle 本をお読みいただけます。
Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector.
The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver).
The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer.
- Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies, including the cancer epigenome atlas
- Discusses targeted isoform specific versus pan-specific inhibitors, a rational drug design approach to epigenetics relevant to pharmacoepigenetic clinical applications
- Covers new findings in the interplay between cancer stem cells (CSCs) and drug resistance, demonstrating that epigenetic machinery is a candidate target for the eradication of these CSCs
"...a helpful reference for researchers and medical professionals interested in epigenetics...contains many resources that may be useful for readers or guide them to technologies and areas of interest quickly. Score: 84 - 3 Stars" --Doody's
The book is a classic multi-author work where each Chapter is prepared by a person or persons well versed in that specific area. The book is primarily for those who already had a reasonable proficiency in many of the areas and are seeking either an expanded view into other areas or depth in the area in which they focus.
The book is divided into five major parts.
Part 1 details much of the scientific background necessary to understand epigenetic factors. This is a now somewhat well understood overview of the basic scientific understanding of epigenetic elements. It covers methylation, histone acetylation, miRNAs, lncRNAs and a variety of other processes. If one has seen some of this previously it is a good overview. If however you are approaching this for the first time this may be a bit too little and a bit too much. The Chapter on methylation is excellent and generally up to date. Methylation on AT nucleotides has recently been observed but its clinical significance is still little understood. The Histone Code could have been presented but that is a nit. Discussions on testing for methylated locations could also have been a bit more detailed but again that is a Lab technique and may have little direct clinical appear. The miRNA chapter is reasonable. I would have liked a more complete and even discussion of DROSHA and DICER but again this is clinical. Finally the lncRNA discussion is quite relevant across a broad base of cancers.
Part 2 discusses applications across a good cross section of cancers. My focus has been melanoma, prostate and MDS so I will focus my attention there. There is an extensive discussion on neurological neoplasia as well as head, neck and throat. Chapter 11 is on prostate cancer. This has been found to be a complex cancer with many genomic presentations. On p 235 the author states “PCa has an unusually low mutation frequency”. I may not fully agree with this but the data is not in. It is however a cancer where methylation plays a role, especially when looking at a putative precursor, HGPIN. The author also presents a short but useful discussion on acetylation as well (p242). The Tables are quite comprehensive and useful as well as current. The other Chapters in this Part seem likewise.
Chapter 8 on hematological cancers is also quite useful. The most interesting case of current study is MDS, which is a methylation result. IN fact hypomethylation therapeutics such as azacitidine is discussed. These drugs have been used in MDS and show some positive value for a year or so but ultimately they fail and AML may occur unless a stem cell transplant is performed. One of the concerns with these therapeutics is their long term system effects. On pp 171-176 there is a good discussion of their identification and evolution. However we may still not really understand their systemic effects.
Part 3 discusses dietary and emerging therapeutic approaches. It also covers several Clinical Trials.
Part 4 examines what they call; Issues and Areas of Concern. Chapter 24 is especially critical. Simply it focuses on Intra Tumor Heterogeneity (ITH). Namely in tumor samples each cell may have a unique genetic activation, and generally there are controlling ones and many followers. We see this for example on PCa. Almost weekly we see some new gene argued for its importance. In reality it may be an inconsequential artifact of some controlling gene not even in the cell we are testing. The ultimate challenge with be cell by cell assessment and profiling in cancers. However the discussion is this Chapter should be read by all who are interested. Chapter 27 is a nice adjunct to the previously discussed Chapter. Here they discuss the therapeutic targeting of cancer stem cells, CSC. This Chapter is worth the read as well.
Part 5 discusses several future directions Specifically in Chapter 29 (pp 687-688) there is a discussion of targeting. Specifically they examine MDM2 as a target to control p53. This is a potentially exciting area. However as we have seen many times once a target is effected we all too often see a new path arise. We now have $100,000 plus treatments that are good for six months. Personalized design is a process; it is an ongoing effort to see what is changing and what new targets are useful.
Overall this is a superb coverage of epigenetics and cancers. It may not cover every niches but it is more than representative. My only negative is the overly small print on the Figures. I have seen this before with this publisher. You may need a lens to read anything on many of the Figures.
I wish I could find more resources as valuable as this one.